Joshua Cohen (left) and Justin Klee (Amylyx)
September 2, 2020 05:07 PM EDTUpdated September 3, 07:15 AM
R&D

Amy­lyx spot­lights a PhII suc­cess in slow­ing ALS pro­gres­sion. And they’re tak­ing it to the FDA

Max Gelman

Senior Editor

Just a cou­ple months af­ter pulling in a $30 mil­lion Se­ries B round, Amy­lyx is mak­ing an­oth­er splash with what it hopes are promis­ing …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

WuXi AppTec will sell cell and gene ther­a­py busi­ness to pri­vate eq­ui­ty firm

J&J part­ners on STAT6; As­traZeneca, Dai­ichi with­draw lung can­cer drug EMA app

BioN­Tech set­tles with NIH, UPenn in Covid vac­cine dis­putes and will pay roy­al­ties

Ca­griSe­ma’s weight loss da­ta dis­ap­point­ed. What does No­vo do next?

Three drug­mak­ers sue US over 340B dis­counts to STD clin­ics they al­lege don’t qual­i­fy

A service from the Financial Times